ReviewEULAR rheumatology open2026
Artificial intelligence in healthcare faces regulatory challenges: balancing innovation with human oversight.
Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) has experienced unprecedented growth in the healthcare sector, promising to revolutionise diagnosis, care, treatment, and biomedical research. This viewpoint article discusses the challenges in this sector and highlights the evolution of the regulatory framework surrounding AI in healthcare and its concrete consequences on innovation. Layered regulatory developments, notably the Medical Device Regulation of 2021 and the AI Act of 2024, have introduced stricter requirements for traceability, clinical performance, risk management, transparency, and human oversight. Although these changes are expected to foster greater trust and accountability among healthcare stakeholders, they also increase the complexity and cost of compliance. These regulatory and organisational challenges represent a turning point for innovative projects in healthcare. Many projects are moving from complex systems toward simpler human-centred tools, whereas others are pushing for collaboration between stakeholders to harmonise existing regulatory frameworks. These combined efforts could lead to more compliant, understandable, and user-friendly solutions for routine care.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.